Search
Mitoquinone
go.drugbank.com/drugs/DB05063Investigational-- where they accumulate up to a thousand fold. … In 2004, a genomic study of hereditary early-onset Parkinson's disease demonstrated a direct molecular link between mitochondrial dysfunction and the pathogenesis of Parkinson's disease.
Flupirtine
go.drugbank.com/drugs/DB06623InvestigationalFlupirtine is a pyridine derivative that is in clinical use as a nonopioid analgesic. It was approved for the treatment of pain in 1984 in Europe.
Paquinimod
go.drugbank.com/drugs/DB13118InvestigationalThe autoimmune attack affects several different organ systems and many patients suffer from serious secondary disease symptoms such as renal disorders as the disease progresses. … Paquinimod is developed for the treatment of SLE (Systemic Lupus Erythematosus), which is an autoimmune disease.
PA-1050040
go.drugbank.com/drugs/DB06039ExperimentalPA1050040, a second generation HIV-1 maturation inhibitor, is a chemical analog of Bevirimat (BVM). It inhibits virus replication by the same mechanism of action as BVM.
Cryptenamine
go.drugbank.com/drugs/DB00785ApprovedCryptenamine is a mixture of closely related hypotensive alkaloids from Veratrum album (Liliaceae). … Cryptenamine has a marked and re-producible depressor effect when given intravenously to hypertensive patients, however the mechanism of action is not known.
AP5346
go.drugbank.com/drugs/DB04992InvestigationalAP5346 is designed to target a diaminocyclohexane platinum (Pt) moiety to tumors through pH-sensitive linkage to a 25 kDa hydroxypropylmethacrylamide polymer.
C31G
go.drugbank.com/drugs/DB05398Investigationalin a phase III pivotal clinical trial for the reduction of sexual transmission of human immunodeficiency virus (HIV). … C31G is a potent broad spectrum antimicrobial agent, effective against gram positive and gram negative bacteria, yeast and fungi.C31G, vaginal gel is developed by Biosyn Inc. and has commenced enrollment
Suvorexant
go.drugbank.com/drugs/DB09034ApprovedInvestigationalSuvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.
Vimseltinib
go.drugbank.com/drugs/DB17520ApprovedInvestigationalin a lower risk of off-target effects, including hepatotoxicity. … [A265035] It is intended to provide a safer alternative to [pexidartinib], a previously approved CSF1R inhibitor associated with significant liver toxicity - the greater selectivity of vimseltinib results
Dialyzable leukocyte extract
go.drugbank.com/drugs/DB16530InvestigationalTransferon is comprised of several peptides mixed from human dialyzable leucocyte extracts and acts as an immunomodulator.